Articles tagged with: Kidney Impairment
Findings from a recent retrospective study conducted at the Mayo Clinic indicate that autologous stem cell transplantation is an effective treatment option for multiple myeloma patients with advanced kidney disease.
The majority of patients (87 percent) responded to the treatment, with 40 percent achieving a complete response. According to the researchers, this complete response rate is similar to those seen in other studies of stem cell transplantation for myeloma patients with kidney disease.
However, the researchers found little evidence that transplantation significantly improves kidney function in patients with advanced kidney …
Results from a recent retrospective analysis conducted in Germany indicate that the combination of Velcade plus Treanda and prednisone is effective for relapsed and refractory multiple myeloma patients with kidney impairment.
Specifically, 67 percent of patients responded to the treatment, and kidney function improved in 86 percent of patients. The study investigators point out that the responses were rapid, with a median time to response of three weeks. With a median progression-free survival of 10 months, some patients experienced a long-term treatment-free interval.
Most of the severe side effects of …
Findings from a recent study indicate that a newer method of determining kidney disease in multiple myeloma patients may be more accurate than traditional methods.
Researchers from Greece found that when they used the newer method, which tests for a protein known as cystatin-C, they were able to detect kidney damage in a higher percentage of newly diagnosed multiple myeloma patients.
The investigators recommend that newer methods that include cystatin-C should be used instead of older methods, which rely only on measures of a compound called creatinine.
However, they note …
This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday.
Sunday started with a poster session in which important new research findings were summarized on posters displayed throughout a large conference hall.
The studies presented during the session were on a wide variety of myeloma-related topics, including new treatments being developed for myeloma, currently used regimens, smoldering multiple myeloma, and findings on initial therapy.
Some of the posters included preliminary results from ongoing clinical trials. Others described …
A team of European researchers recently found that advanced age, kidney failure, infections, heart and gastrointestinal complications, and drug discontinuation are associated with poor survival among elderly myeloma patients.
The results are from a combined analysis of data from four major European clinical trials. All the trials involved elderly multiple myeloma patients treated with either conventional anti-myeloma agents or combinations of conventional and novel agents.
The study also found that intensive anti-myeloma treatment regimens – that is, regimens combining conventional agents with more than one novel agent – may be …